Open Access. Powered by Scholars. Published by Universities.®
- Discipline
- Keyword
-
- Adult (1)
- Adult; article; B lymphocyte; binding site; blood cell; blood volume; cell lineage; controlled study; erythrocyte; gene control; gene expression; gene expression profiling; gene identification; genetic variability; granulocyte; hematopoietic cell; human; human cell; human experiment; male; normal human; quantitative analysis; reverse transcription polymerase chain reaction; T lymphocyte; transgene (1)
- Anemia (1)
- Anemia, Sickle Cell (1)
- Antisickling Agents (1)
-
- Atrial (1)
- Brain Ischemia (1)
- Cardeza Foundation for Hematologic Research (1)
- Chelation in Sickle-Cell-Disease (1)
- DFP versus DFO in Sickle-Cell-Disease (1)
- Department of Medicine (1)
- Echocardiography (1)
- Echocardiography, Transesophageal (1)
- Effectiveness of Deferiprone in Sickle-Cell-Disease (1)
- Female (1)
- Heart Septal Defects (1)
- Heart Septal Defects, Atrial (1)
- Humans (1)
- Hydroxyurea (1)
- Philadelphia (1)
- Sickle Cell (1)
- Stroke (1)
- Thomas Jefferson University (1)
- Transesophageal (1)
- Treatment Outcome (1)
Articles 1 - 3 of 3
Full-Text Articles in Medicine and Health Sciences
Microrna Expression Differences In Human Hematopoietic Cell Lineages Enable Regulated Transgene Expression., Raúl Teruel Montoya, Xianguo Kong, Shaji Abraham, Lin Ma, Satya P Kunapuli, Michael Holinstat, Chad A Shaw, Steven E. Mckenzie, Leonard Edelstein, Paul Bray
Microrna Expression Differences In Human Hematopoietic Cell Lineages Enable Regulated Transgene Expression., Raúl Teruel Montoya, Xianguo Kong, Shaji Abraham, Lin Ma, Satya P Kunapuli, Michael Holinstat, Chad A Shaw, Steven E. Mckenzie, Leonard Edelstein, Paul Bray
Cardeza Foundation for Hematologic Research
Blood microRNA (miRNA) levels have been associated with and shown to participate in disease pathophysiology. However, the hematopoietic cell of origin of blood miRNAs and the individual blood cell miRNA profiles are poorly understood. We report the miRNA content of highly purified normal hematopoietic cells from the same individuals. Although T-cells, B-cells and granulocytes had the highest miRNA content per cell, erythrocytes contributed more cellular miRNA to the blood, followed by granulocytes and platelets. miRNA profiling revealed different patterns and different expression levels of miRNA specific for each lineage. miR-30c-5p was determined to be an appropriate reference normalizer for cross-cell …
Deferiprone Versus Deferoxamine In Sickle Cell Disease: Results From A 5-Year Long-Term Italian Multi-Center Randomized Clinical Trial., Giusi Calvaruso, Angela Vitrano, Rosario Di Maggio, Samir K. Ballas, Martin H Steinberg, Paolo Rigano, Massimiliano Sacco, Paul Telfer, Disma Renda, Rita Barone, Aurelio Maggio
Deferiprone Versus Deferoxamine In Sickle Cell Disease: Results From A 5-Year Long-Term Italian Multi-Center Randomized Clinical Trial., Giusi Calvaruso, Angela Vitrano, Rosario Di Maggio, Samir K. Ballas, Martin H Steinberg, Paolo Rigano, Massimiliano Sacco, Paul Telfer, Disma Renda, Rita Barone, Aurelio Maggio
Cardeza Foundation for Hematologic Research
Blood transfusion and iron chelation currently represent a supportive therapy to manage anemia, vasculopathy and vaso-occlusion crises in Sickle-Cell-Disease. Here we describe the first 5-year long-term randomized clinical trial comparing Deferiprone versus Deferoxamine in patients with Sickle-Cell-Disease. The results of this study show that Deferiprone has the same effectiveness as Deferoxamine in decreasing body iron burden, measured as repeated measurements of serum ferritin concentrations on the same patient over 5-years and analyzed according to the linear mixed-effects model (LMM) (p=0.822). Both chelators are able to decrease, significantly, serum ferritin concentrations, during 5-years, without any effect on safety (p=0.005). Moreover, although …
Primary Stroke In A Woman With Sickle Cell Anemia Responsive To Hydroxyurea Therapy., Samir K. Ballas, Ubaldo E. Martinez-Outshoorn, Michael P. Savage
Primary Stroke In A Woman With Sickle Cell Anemia Responsive To Hydroxyurea Therapy., Samir K. Ballas, Ubaldo E. Martinez-Outshoorn, Michael P. Savage
Cardeza Foundation for Hematologic Research
The most common cause of stroke in children with sickle cell anemia is infarction due to ischemia. In adults, however, stroke is most commonly hemorrhagic in nature. Other causes of stroke in patients with sickle cell disease are very rare. In this short communication, we describe a woman with sickle cell anemia responsive to hydroxyurea (HU) therapy who had primary stroke due to paradoxical embolization caused by a large atrial septal defect. Successful management of the stroke included surgical closure of the defect with trans-esophageal echocardiographic guidance. To the best of our knowledge, this is the first patient with sickle …